JENAVALVE ANNOUNCES FIRST IMPLANTATION OF TRANSAPICAL TAVI SYSTEM IN POLAND

Company Continues to Expand Commercialization of Second-Generation Device in Europe

Wilmington, Delaware and Munich, Germany – December 23, 2013 – JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today that it has successfully completed the first implantation of its second-generation transapical JenaValve TAVI system in Poland.

The implantation was performed by cardiac surgeon Robert Sobczynski, M.D., and Prof. Dariusz Dudek in the Department of Cardiovascular Surgery and Transplantology in John Paul II Hospital, Krakow, Poland. PD Walter Eichinger, M.D., chief physician and head of the heart surgery department at the Munich Municipal Hospital Group, Munich, Germany, served as proctor to support the implantations.

"We treated an 86 years old patient with a severely calcified aorta who was declined for open heart surgery due to his comorbidities with the transapical JenaValve TAVI system. We have chosen this specific system because of its unique design and features." Dr. Sobczynski explained. "The JenaValve consists of a self-expanding Nitinol stent and is fixed in the aorta with a so called clipping mechanism. These two features are beneficial for these kinds of patients because the prosthesis does not put stress on annulus and aorta and thus reduces the risk for any dissection."

"And thanks to the 3 feelers of the prosthesis, the JenaValve is guided into the anatomically correct position, ensuring to reach the exact positioning height." Dr. Sobczynski added.

The first JenaValve implantation in Poland underlines company´s approach to further distribute the unique JenaValve TAVI system across Europe, Helmut J. Straubinger, CEO of JenaValve Technology, commented.

"It again proves the market need for our 2nd generation TAVI system. The JenaValve TAVI system has an edge over currently available competitive devices and physicians all across the European countries appreciate these advantages. We really appreciate offering our TAVI system to physicians and patients in Poland."

About TAVI

Transcatheter aortic valve implantation (TAVI) systems have already yielded nearly $1 billion in revenues worldwide and the market is expected to grow to over $3 billion in 2016[1]. Clinicians are now focused increasingly on TAVI technical and procedural refinements and advancements found in second-generation products such as JenaValve's that address and resolve issues including ease of implantation, the need for post-procedure pacemaker implantation and post-implant paravalvular leakage.

About the JenaValve™ TAVI System

The JenaValve is a true second-generation catheter-based aortic valve implantation system engineered and manufactured to the highest quality standards. The JenaValve transapical TAVI system is currently

being sold in Europe. The First-in-man trail for the company's transfemoral TAVI system started in December 2013 and is anticipated to be commercial available end of 2014.

- **The JenaValve prosthesis** consists of a natural aortic porcine root bioprosthesis fitted with an outer porcine pericardial patch, a so-called skirt, before being sewn onto a Nitinol self-expanding stent. The high-quality bioprosthesis is durable, ensuring long-term aortic valve function.

- **JenaValve's unique "3-feeler element"** allows the clinician to accurately position the prosthesis in the anatomically correct position during implantation thus ensuring to achieve the correct implantation height and commissural alignment within the patient's native valve.

- **JenaClip™ anchoring and clipping mechanism** allows the valve to be clipped onto the patient's native valve leaflets enabling the JenaValve to be firmly anchored in the correct anatomical position and provide active fixation and resistance to migration independent from the calcification level of the native valve.

- **The JenaValve implantation** is conducted on the beating heart. Hemodynamic flow is maintained without cardiac arrest and rapid pacing is not required during the procedure. The low profile of the stent prosthesis ensures open flow to the coronaries after the implantation. The JenaValve is available in three sizes, 23mm, 25mm and 27mm, covering aortic valve annuli from 21mm to 27mm.

- **JenaValve is retrievable and repositionable** thereby contributing to a successful procedure and confidence of the clinician.

About JenaValve Technology, Inc.

JenaValve Technology, Inc., a U.S. corporation with primary operations in Munich, Germany, develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. JenaValve was founded in 2006 by cardiologists and inventors Prof. Hans R. Figulla, M.D. and Prof. Markus Ferrari, M.D.. The Company's transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide. JenaValve is backed by world-class U.S., European and Asian investors. Additional information is available at www.jenavalve.com

European Contact: JenaValve Technology Inc. and JenaValve Technology, GmbH, Munich (Germany) +49 895 527 9080 or info@jenavalve.de

U.S. Contact: Rene Caron, Allen & Caron Inc. +1-949 474 4300 or rene@allencaron.com

1) Goldman Sachs Global Investment Research